Drug Profile
Research programme: cancer immunotherapeutics - Concentra Biosciences
Alternative Names: Myeloid-functional TIM-3 antibodiesLatest Information Update: 15 May 2023
Price :
$50
*
At a glance
- Originator Jounce Therapeutics
- Developer Concentra Biosciences
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 May 2023 Jounce Therapeutics has been acquired and merged into Concentra Biosciences
- 10 Aug 2021 Phase-I clinical trials in Solid tumours in USA (Parenteral) before August 2021 (Bristol-Myers Squibb pipeline, August 2021)
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb